FDA Sets Rules for Doctor-Facing Skin Cancer Screening Software
Published Date: 10/30/2026
Rule
Summary
The FDA is officially classifying a special software tool that helps doctors check skin spots that might be cancer into a safer, easier-to-manage category called Class II. This change, effective October 30, 2026, means the device will have clear safety rules but face fewer hurdles, helping patients get access to new tech faster. Doctors and device makers will benefit from this smoother process without extra costs or delays.
Analyzed Economic Effects
6 provisions identified: 4 benefits, 2 costs, 0 mixed.
Class II listing speeds patient access
You may get access to this type of physician‑used skin‑lesion diagnostic software faster because FDA classified it into Class II, which the FDA says reduces regulatory burdens. The order is effective October 30, 2026, and FDA states the classification was applicable January 12, 2024.
510(k) premarket notification required
If you make these devices, you must submit a premarket notification under section 510(k) to market them because FDA has not exempted this device type from 510(k) requirements. The rule retains the device as subject to the 510(k) process.
Minimum 90% sensitivity for high‑risk lesions
Standalone device testing must demonstrate at least 90 percent sensitivity for lesions with high metastatic potential, or provide clinical justification for a lower sensitivity; clinical justification must also be provided for reported specificity. This numeric sensitivity threshold is an explicit special control in the rule.
Clinical testing must show superior user accuracy and diversity
Clinical data must demonstrate that device‑aided users are more accurate in diagnosing the indicated lesions than unaided users, and testing must include patients across a range of skin phototypes, risk factors, and anatomic areas that represent the intended use population. The rule requires subgroup analysis by relevant risk factors.
Extensive testing and possible postmarket surveillance
If you make these devices, you must perform non‑clinical performance testing, precision/repeatability testing, electrical/thermal/mechanical and electromagnetic safety testing, biocompatibility evaluation, validation of reprocessing for reusable parts, software verification/validation and hazard analysis, human factors assessment, and compatibility testing with acquisition hardware; FDA may also require postmarket surveillance to demonstrate performance under anticipated use.
Detailed labeling and explicit warnings required
Labeling must include a summary of standalone and clinical performance (including sensitivity, specificity, and confidence intervals), a description of the patient population used to develop or train the algorithm, device limitations and subpopulations not validated, interpretation guidance and risk warnings (for example, excluding lesions close to the eye), a statement that the device is not for standalone diagnosis, and instructions for maintenance and validated reprocessing.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-20848, Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods
The FDA is changing food rules to allow salt substitutes in many standardized foods, helping companies make lower-sodium options. This move aims to cut heart disease risks by reducing sodium without changing how foods basically taste or look. The new rule kicks in December 14, 2026, and food makers have until November 12, 2026, to raise any concerns, with no big costs expected.
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
Previous / Next Documents
Previous: 2026-22176, Dimethyl Sulfoxide in Pesticide Formulations; Exemptions From the Requirement of a Tolerance
The EPA is giving a green light to use dimethyl sulfoxide (DMSO) in certain pesticide products without setting strict residue limits. This change helps farmers, food makers, and pesticide companies by cutting red tape and making it easier to use DMSO safely on crops, animals, and food surfaces. The new rule kicks in on October 30, 2026, with a chance to raise concerns by December 29, 2026.
Next: 2026-22180, Medical Devices; Radiology Devices; Classification of the Radiology Software for Referral of Findings Related to Fibrotic Lung Disease
The FDA is officially putting radiology software that helps spot fibrotic lung disease into a safer, easier-to-manage category called Class II. This change, effective October 30, 2026, means the software will have special safety rules but face fewer hurdles, helping patients get access to new tech faster. Doctors, hospitals, and software makers will feel the impact, with smoother approval and no surprise costs.